Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07172152 · ClinicalTrials.gov registry record · NA
Improving Minority Health Through Biofeedback and Stress Reduction
A NA study of Anxiety and Emotional Regulation, sponsored by Amelia Saul, PhD, CTRS, BCB.
- Recruiting
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT07172152: Recruiting NA study of Anxiety and Emotional Regulation, sponsored by Amelia Saul, PhD, CTRS, BCB.
NCT07172152 is a NA study of Anxiety and Emotional Regulation that is actively recruiting participants, run by Amelia Saul, PhD, CTRS, BCB. The registered enrollment target is 64 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07172152, a NA study of Anxiety and Emotional Regulation, is actively recruiting participants, sponsored by Amelia Saul, PhD, CTRS, BCB.
- RECRUITING
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to evaluate the effectiveness of a four-week heart rate variability (HRV) biofeedback intervention to improve physiological stress response, emotion regulation, and anxiety-related symptoms in young ethnic minority adults with a family history of cardiovascular disease (CVD). Participants will be randomly assigned to either an intervention group, where they will engage in guided paced breathing exercises, or a control group, which will follow standard conditions without the intervention. The study consists of five sessions, including an initial assessment, three weekly check-in sessions, and a final post-intervention assessment. Participants will practice paced breathing at home and attend brief in-lab sessions to track progress. Physiological and psychological measures, such as HRV, GSR, BP, anxiety levels, and responses to the Socially Evaluated Cold Pressor Test (SECPT), will be used to assess outcomes. Findings from this study may provide insights into accessible, non-invasive stress management interventions to mitigate CVD risk in high-risk populations.
Primary Outcome
HRV will be assessed using the OptimalHRV sensor to determine improvements in autonomic regulation and stress resilience.
Conditions Studied
Interventions
- BEHAVIORAL HRV Biofeedback Training
Study Locations (1)
Florida
- Florida International University - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT07172152 shows while recruiting
NCT07172152 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (85% lower).
The record links to 6 conditions, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which HRV Biofeedback Training is the first listed.
NCT07172152 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07172152 about?
NCT07172152 is a clinical study titled "Improving Minority Health Through Biofeedback and Stress Reduction". This study aims to evaluate the effectiveness of a four-week heart rate variability (HRV) biofeedback intervention to improve physiological stress response, emotion regulation, and anxiety-related symptoms in young ethnic minority adults with a family history of cardiovascular disease (CVD). Partici...
What is the current status of trial NCT07172152?
This trial is currently recruiting. It is a NA study. The enrollment target is 64 participants. The study started on 2025-09-15. Estimated completion is 2026-08.
What conditions does trial NCT07172152 study?
This clinical trial studies the following conditions: Anxiety, Emotional Regulation, Health Disparities, Chronic Stress, Cardiovascular Disease Risk Reduction.
What interventions are being tested in trial NCT07172152?
The interventions under investigation include: HRV Biofeedback Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT07172152?
This trial is sponsored by Amelia Saul, PhD, CTRS, BCB, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07172152 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07172152's enrollment target sits among peer trials
64 224th of 364 higher than 138 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
-
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
RECRUITING · NA
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI